HTB

2008

WHO recommends treating all HIV-infected infants aged less than 12 months

Plasma concentrations and virologic evaluations after stopping NNRTI treatment in PENTA 11

Elite control of a virus that caused AIDS in the transmitting partner

Presentations from the May 21-23 HIV Vaccine Trials Network (HVTN) Meeting

Failure of STEP leads TAG to criticise the proposed PAVE100A vaccine trial

Free osteopathy for people with HIV at the British School of Osteopathy

AIDS denialists shut out of Senate hearing after winning “whistleblower” award

MTV internet game challenges ignorance and assumptions about who has HIV

PRN notebook

JACI special issue on prospects for eradication

New resources from HIV InSite

Overview of mucosal transmission

Volume 9 Number 7/8 Jul/Aug 2008 PDF

Volume 9 Number 5/6 May/June 2008

14th Annual BHIVA Conference, 23-25 April 2008, Belfast

Overview of MRC studies in 2008

Initial results of BHIVA audit of HIV-related inpatient and day care in the UK

Monitoring patients on antiretroviral therapy in resource-limited settings with viral load, CD4 count, or clinical observation alone

Lower bilirubin increases in HCV-positive patients using atazanavir

Cases of ventricular tachycardia and atazanavir/r and methadone

Choice of ARVs for people after organ transplantation

Use of fibroscan as non-invasive alternative to liver biopsy in HCV/HIV coinfection

New-fill used to treat lipoatropy in feet

Effect of 100mg ritonavir once- and twice-daily on lipids and cardiovascular markers in HIV-negative volunteers

15th Conference on Retroviruses and Opportunistic Infections, Boston, 2-6 February 2008

Immediate HAART reduces death and AIDS progression over 48 weeks in patients with acute OIs

Utility of routine viral load, CD4 count and clinical monitoring among HIV-positive adults in rural Uganda

Implementation of more complex regimens for prevention of mother-to-child transmission of HIV in Rwanda

The estimated cost of switching from d4T to TDF in South Africa

Gender differences in viral load by CD4 count in men and women

Immune reconstitution inflammatory syndrome in young children initiating ART

Complications with BCG vaccination in HIV-positive and negative infants: CHER Study

The association between clinical characteristics and HIV-infection in very young infants

Safety and efficacy of boosted darunavir in treatment-experienced children and adolescents at 24 weeks

Responses to atazanavir-containing HAART in treatment-naive children in South Africa

Initial growth, CD4, and viral load responses to HAART in Ugandan compared to UK/Irish HIV-positive children

Paediatric pharmacokinetic studies

A pilot study of three treatment strategies for HIV-positive infants

Key patient safety concern removed in new FDA guidance for non-US trials

FDA approval of generic ARVs

Tibotec issue Dear Doctor letter and FDA require darunavir label change relating to hepatotoxicity

Draft BHIVA treatment guidelines online for comment

Atazanavir 300mg capsule available

Raltegravir approved in Scotland

Abacavir, ddI and risk of heart attack: additional published data and statements from the EMEA and FDA

US paediatric guidelines updated (2008)

New paediatric dosing recommendations for atazanavir

Understanding control of HIV replication in the absence of therapy

A surreal, deeply troubling week for AIDS vaccine research

IAS calls for immediate release of Chinese activist

Thailand’s war on drugs will undermine national AIDS fight and human rights: police given licence to kill drug users

Activists criticise AIDS conference on opening day: Russian ban on substitution drug treatment is an ‘Iron Curtain’ to ARV treatment

Opportunities for healthcare workers to volunteer overseas

Conference reports and abstracts: 9th International Workshop on Clinical Pharmacology of HIV Therapy and 6th European HIV Drug Resistance Workshop

New UK support group for gay men with HIV/HCV coinfection

HCV pipeline report

IHRD Harm Reduction Report

TB – Online medical resources

Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk

Volume 9 Number 5/6 May/June 2008 PDF

Volume 9 Number 3/4 March/April 2008

i-Base funding withdrawn: urgent request for letters of support

15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston

Atazanavir/r vs lopinavir/r in treatment-naive patients: 48 week results

Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality

Post navigation